Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
August 4, 2025 2:10 PM EDTTD Cowen analyst Ritu Baral reiterated a Buy rating and $61.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).
The analyst comments "Our Take: We are highly encouraged by today's data which we believe bodes well for PBO-controlled POWER1 Ph2/3 vormatrigene data due by... More
Praxis Precision Medicines Inc. (PRAX) PT Raised to $33 at Wedbush
August 4, 2025 1:24 PM EDTWedbush analyst Laura Chico raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $33.00 (from $28.00) while maintaining a Underperform rating.
The analyst comments "Remain Underperform rated on PRAX, new $33 target. While the headline figure for seizure reduction with vormatrigine represented... More
Praxis Precision Medicines Inc. (PRAX) PT Raised to $155 at Guggenheim
August 4, 2025 12:58 PM EDTGuggenheim analyst Yatin Suneja raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $155.00 (from $120.00) while maintaining a Buy rating.
The analyst comments "Key Message: In the open-label RADIANT study (n=37), vormatrigine demonstrated an impressive 56.3% reduction in monthly seizure frequency... More
